Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
Start Date
1/5/2026
Completion Date
1/29/2029
Summary
The purpose of this study is to assess how well nipocalimab works when compared to efgartigimod in participants with generalized myasthenia gravis (a condition in which body's immune system mistakenly attacks and damages the connection between nerves and muscles causing muscle weakness).
Eligibility Criteria
Age Range: 18 years to 74 years
Interventions
Nipocalimab
Efgartigimod
Conditions
Locations
Neurology Center of North Orange County
Fullerton, California 92835
United States
The Neurology Group
Pomona, California 91767
United States
Advanced Neurology of Colorado
Fort Collins, Colorado 80528
United States
University of Connecticut
Farmington, Connecticut 06030
United States
SFM Clinical Research LLC
Boca Raton, Florida 33487
United States
HSHS St. Elizabeth's Hospital
O'Fallon, Illinois 62269
United States
Josephson Wallack Munshower Neurology, PC
Indianapolis, Indiana 46256
United States
Tulane Center for Clinical Research
New Orleans, Louisiana 70112
United States
Henry Ford Hospital
Detroit, Michigan 48202
United States
Equity Medical
New York, New York 10023
United States
Velocity Clinical Research, Inc.
Raleigh, North Carolina 27607 6010
United States
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina 27157
United States
Neurology Clinic, PC
Cordova, Tennessee 38018
United States
Texas Neurology
Dallas, Texas 75206
United States
Rambam Medical Center
Haifa, 3109601
Israel
Sourasky Medical Center
Tel Aviv, 6423906
Israel
HOCH Health Ostschweiz Kantonsspital St.Gallen
Sankt Gallen, 9007
Switzerland